Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence

NCT04782804 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Cholangiocarcinoma, Intrahepatic

Interventions

DRUG: Capecitabine
DRUG: PD-1 Antibody（Tislelizumab）

Sponsor

Fudan University